Q-omics provides the consensus-scored KRT18 profile across patient tissues and cancer cell-line models. KRT18 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KRT18 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, KRT18 protein abundance shows 16,951 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, COAD, and BRCA as cancer lineages where KRT18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT18 survival associations across molecular data types. KRT18 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT18 RNA expression–survival associations across cancer types. High KRT18 expression shows unfavorable associations in LUAD, PAAD, LGG and ESCA, but favorable associations in UCEC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KRT18 RNA expression.
This table summarizes KRT18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KRT18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT18 shows higher tumor expression in COAD, KIRP, LUAD, KIRC, BLCA and STAD. The COAD box plot shows higher KRT18 RNA expression in tumor versus normal tissue (log2 FC = +1.518, t-test p < 0.001).
This table shows molecular features associated with KRT18 in patient tissues and cancer cell lines. In patient samples, KRT18 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
